Umbilical cord blood transplants improve cancer survival rates across all races

Gen­e­sis Ther­a­peu­tics, a start­up us­ing ar­ti­fi­cial in­tel­li­gence to de­sign small mol­e­cule drugs, has raised $200 mil­lion in Se­ries B fi­nanc­ing — one of the largest

Ab­b­Vie is team­ing up with Sim­cere Za­im­ing to de­vel­op an in­ves­ti­ga­tion­al new drug can­di­date for mul­ti­ple myelo­ma. The agree­ment, an­nounced Mon­day … Sign up to